Recursion Pharmaceuticals EBIT

As of the most recent data (June 2026), RXRX shows a EBIT of $-560M. That compares with $-640M in the prior-year period — up 12.5% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RXRX's EBIT is now $-560M (was $-640M) — a 12.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Recursion Pharmaceuticals is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Recursion Pharmaceuticals is at $-560M, which is lower that average. That is roughly 102.5% below the sector mean. Use the comparison chart on this page to see how RXRX stacks up against individual peers as well.

Tracking RXRX's ebit over time shows whether Recursion Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-560M That compares with $-640M in the prior-year period — up 12.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Recursion Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-560M) with ownership activity and broader fundamentals.